COMMUNIQUE DE PRESSE *Paris, France – 13 septembre 2022*





SiVIEW, a specialist in AI-driven visual diagnostics, announces with LBO France a capital increase of €5.5M

The funds will allow the acceleration of SiVIEW's growth and R&D roadmap with the ambition of revolutionizing visual health care.

SiVIEW is a French start-up which has developed a unique artificial intelligence technology that enables reliable, accurate, and fast eye examinations to be performed. This can be delegated by the healthcare professional in order to focus on the patient and optimize the overall care plan. SiVIEW announces that it has raised €5.5M in a Series A round with LBO France's Digital Health 2 fund to accelerate its global expansion and R&D roadmap.

While the need for reliable visual diagnostics is constantly increasing (e.g., due to a pandemic of myopia, increased screen-time, and an aging population), the number of experts able to perform the required examinations is decreasing, and SiVIEW has designed a disruptive innovation that allows quick and easy eye examinations, that are both precise and detailed, to be performed intuitively to support diagnosis and prescription.

Founded by vision specialists, SiVIEW addresses a global health issue: to obtain the correct prescription simply and quickly, regardless of the complexity of the visual profile.

Marketed after 6 years of R&D, the SiviewExam[®] solution is compatible with almost all optical equipment on the market and offers quality results (measurements and reports) in less than 8 minutes. It supports the decision-making process, allowing the vision expert to save time and improve efficiency for better patient care. The solution is already used in many European countries and is experiencing a strong growth phase that will accelerate with access to the North American and Asian markets.

Just a few days before two major industry trade shows, ESCRS in Milan and SILMO in Paris, SiVIEW has completed this fundraising to:

- Accelerate its international growth by increasing its investments in sales, marketing, and R&D (e.g., new testing and analysis modules, enhanced instrument interconnectivity, new innovation techniques);
- Position the company as a key player in the management of visual disorders worldwide.

Laure Pichereau, CEO & Co-founder of SiVIEW: "Our ambition from the beginning was to become the reference in artificial intelligence-driven eye exams. Once the SiVIEW solution was ready for commercialization, we received the support of major optical and ophthalmology chains in France and abroad. We are honored to welcome LBO France, leading specialist in digital health, as an investor and partner. I am personally very pleased with the trusting relationship that we have built together and which will enable us to work efficiently in this new phase of growth. I would also like to thank our historical investors, CARENCEAU and FIME, for their unwavering support since they joined the capital structure in 2018."

Franck Noiret, Managing Director of LBO France: "We are very pleased to partner with SiVIEW and its founders who are recognized experts in the field. With its dual expertise in AI and optometry, SiVIEW has developed a unique software solution based on an intelligent and intuitive algorithm that automates eye exams and improves patient care. Commercialized in SaaS mode, the SiVIEW solution is aimed at the global market. This is the 7th investment of our Digital Health 2 fund, which is dedicated to financing innovative digital health companies in Europe. We are delighted to support them in their ambitious international development."

About SiVIEW

SiVIEW was created in 2016 by Laure Pichereau & Jérôme Perderiset, two vision specialists with a passion for clinical practice, proven academic backgrounds at the University of Paris XI – Orsay, and more than 20 years of experience in Optics. The company has developed an innovative software solution based on artificial intelligence to automate the diagnosis of the visual function and to offer the practitioner the means to practice serenely and efficiently, while providing the patient with better access to care.

SiVIEW is a team of 30 people, the aggregation of multiple and highly specialized skills, the filing of numerous patents (8 to date), and the development of a breakthrough technology. It is based on a monthly subscription business model (SaaS) which allows a flexible commercial relationship in which the client can develop the product and its use according to its needs and the technological advances which regularly enhance the value proposition.

News

Participation at ESCRS from 16 to 20 September in Milan, on the Rexxam stand (1st floor, Hall B, stand: 2Y13/19) and at SILMO from 23 to 26 September in Paris, on the Novacel stand (stand 6-D-27) and Fax international (stand 5A-L-53)

Find out more: www.siviewtech.com

Media contacts

SiVIEW: Jérôme Perderiset, Healthcare & Marketing Director & Co-Founder: jerome@siview.fr / +33 6 52 78 16 01

Panacee: Céline Hollinger: c.hollinger@panacee.fr

About LBO France

A pioneer in private equity in France, LBO France is today a leading multi-specialist investment platform with €5.4 billion under management including participating interests in Twenty-First Capital in France and Polis Fondi SGR in Italy. Its investment strategy is based on five distinct segments managed by dedicated teams: Mid and Small Cap LBO, Digital Health Venture, Real Estate and Proptech, Infrastructure Debt, and Listed Investment. For several years, the Company has expanded its activities in Europe, particularly in Italy with teams in Milan and Rome, as well as on the African continent. Wholly owned by its managers, LBO France is one of the founding members of the International Climate Initiative and one of the first signatories of the France Invest charter for parity.

Find out more: www.lbofrance.com

Média contacts - Taddeo:

Antoine Denry: +33 (0)6 18 07 83 27 / antoine.denry@taddeo.fr Julia Paget: +33 (0)6 38 55 68 78 / julia.paget@taddeo.fr